NMTC Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Product Revenue: $2.9 million, down from $3.3 million in Q1 2025 (which included initial stocking orders).
Sequential Growth: Revenue increased by 5.5% from $2.7 million in the previous quarter.
Gross Profit: $1.6 million (54.2% of revenue), compared to $1.9 million (58.9% of revenue) in Q1 2025.
Operating Expenses: Totaled $3.3 million, slightly up from $3.2 million in Q1 2025.
Net Loss: $1.4 million, or $0.03 per share, compared to a net income of $1.8 million, or $0.06 per share, in the prior year.
Cash Position: $3.6 million as of December 31, 2025, down from $6.6 million at the end of September 2025.
Working Capital: $6.8 million, down from $7.9 million in the previous quarter.

2. Strategic Updates and Business Highlights

1RF Brain Ablation System: Nearly half of all ablations since launch were performed in Q1 2026, indicating strong market adoption. A patient success story was highlighted.
Registry Development: A registry to capture patient outcomes is expected to enroll its first patient by the end of Q3 2026.
International Expansion: The company is pursuing ISO 13485 certification to facilitate international commercialization.
1RF Trigeminal Nerve Ablation System: Limited commercial launch initiated, with nine patients treated across three centers, all reporting pain relief.
Drug Delivery Program: Accelerated timeline for devices to be available for clinical studies by Q3 2026, six months ahead of schedule.
Lower Back Pain Management: Initiating animal studies for a new needle technology and validating the basivertebral nerve ablation system through advisory board meetings.

3. Forward Guidance and Outlook

Revenue Projection: Anticipating at least $10.5 million in sales for fiscal year 2026, representing a minimum 17% increase from fiscal year 2025.
Operational Expectations: SG&A expenses expected to remain flat, while R&D expenses may fluctuate based on project phases.

4. Bad News, Challenges, or Points of Concern

Declining Revenue: Year-over-year product revenue decreased due to the absence of initial stocking orders from Zimmer.
Net Loss: Significant shift from net income in the prior year to a net loss this quarter raises concerns about profitability.
Cash Burn: The decrease in cash reserves could pose challenges for funding operations if revenue growth does not accelerate.
Market Uncertainty: The company faces competitive pressures and must successfully navigate strategic discussions for licensing and partnerships.

5. Notable Q&A Insights

Trigeminal Nerve System: Nine cases were completed at three centers, with ongoing diligence discussions for potential licensing.
Clinical Feedback: Positive feedback from neurologists and surgical teams regarding the ease of use and effectiveness of the ablation devices.
Sales and Marketing: Marketing responsibilities lie with Zimmer, which is expected to manage commercialization costs.
Future Studies: Animal studies for drug delivery and spinal cord technologies are set to ramp up in the latter half of the fiscal year.

Overall, NMTC is experiencing a mix of positive developments in product adoption and strategic initiatives, but faces challenges in revenue generation and profitability. The outlook remains cautiously optimistic with a focus on growth in 2026.

NMTC — NeuroOne Medical Technologies Corporation